For example, crizotinib that bound to the ATP-binding site of ALK kinase domain was the first ALK inhibitor approved by the U.S. FDA in 2011 in the first-line treatment of ALK-positive NSCLC patients (Cui et al., 2011). This evidence concerns the gene ALK and non-small cell lung carcinoma.